

Antibiotic Resistance Mechanisms Inform Discovery: Identification and Characterization of a Novel Amycolatopsis Strain Producing Ristocetin

Andrew W. Truman,^{a*} Min Jung Kwun,^b Jinhua Cheng,^c Seung Hwan Yang,^c Joo-Won Suh,^{d#}
Hee-Jeon Hong^{b#}

Department of Chemistry, University of Cambridge, Cambridge, United Kingdom^a; Department of Biochemistry, University of Cambridge, Cambridge, United Kingdom^b; Center for Neutraceutical and Pharmaceutical Materials, Myongji University, Yongin, Republic of Korea^c; Division of Bioscience and Bioinformatics, College of Natural Science, Myongji University, Yongin, Republic of Korea^d

Running Title: Antibiotic Resistance Mechanisms Inform Discovery

#Address correspondence to Joo-Won Suh, jwsuh@mju.ac.kr, or Hee-Jeon Hong, hh309@cam.ac.uk.

*Present address: Andrew W. Truman, Department of Molecular Microbiology, John Innes Centre, Norwich, United Kingdom.

A.W.T., M.J.K. and J.C. contributed equally to this work.

25

26 **ABSTRACT**

27

28 Discovering new antibiotics is a major scientific challenge, made increasingly urgent by the continued
29 development of resistance in bacterial pathogens. A fundamental understanding of the mechanisms of
30 bacterial antibiotic resistance will be vital for the future discovery or design of new, more effective
31 antibiotics. We have exploited our intimate knowledge of the molecular mechanism of glycopeptide
32 antibiotic resistance in the harmless bacterium *Streptomyces coelicolor* to develop a new two-step cell
33 wall bioactivity screen that efficiently identified a new actinomycete strain containing a previously
34 uncharacterized glycopeptide synthetic gene cluster. The screen first identifies natural product extracts
35 capable of triggering a generalized cell wall stress response mechanism, then subsequently specifically
36 selects for glycopeptide antibacterials by assaying for induction of glycopeptide resistance genes. In
37 this study, we have established a diverse natural product extract library from actinomycetes strains
38 isolated from locations with widely varying climates and ecologies and screened them using the novel
39 two-step bioassay system. The bioassay ultimately identified a single strain harboring the previously
40 unidentified biosynthetic gene cluster for the glycopeptide ristocetin providing a proof-of-principle for
41 the effectiveness of the screen. This is the first report of the ristocetin biosynthetic gene cluster which is
42 predicted to include some interesting and previously uncharacterized enzymes. By focusing on
43 screening libraries of microbial extracts this strategy provides the certainty that identified producer
44 strains are competent for growth and the biosynthesis of the detected glycopeptide under laboratory
45 conditions.

46

47

48 **INTRODUCTION**

50 Recent years have seen ever increasing numbers of cases of infections caused by drug-resistant
51 bacteria, creating an urgent need for new and improved antibiotics (1). Unfortunately, traditional
52 antibiotic research and development has decreased during this period leading to a reduction in the
53 antibiotic discovery pipeline and a developing public health crisis. Understanding how antibiotics can
54 fail to be active is vital knowledge for the development of future novel antimicrobials. Such
55 information is often linked intimately to the drug's mode of action, and therefore can provide unique
56 insights that can be used to help discover and design novel compounds, or to develop new ways of
57 prolonging the therapeutic usefulness of existing ones. Such efforts can be assisted by recent advances
58 in genetic engineering and synthetic biology approaches that will facilitate the targeted modification of
59 existing antibiotic structures (2). These techniques however rely on the supply of a diverse range of
60 well characterized antibiotic scaffold-modifying enzymes to be called upon to specifically expand the
61 chemical diversity of the natural structures available. The discovery of new enzyme activities can
62 therefore be seen as an important goal in itself, alongside the larger goal of identifying novel natural
63 antibiotics.

64 The bacterial cell wall is an important and validated target for antibacterial chemotherapy; it is
65 crucial for bacterial cell growth by providing a physical protective barrier between the cell and its
66 environment, and is an important mediator of the innate immune response during bacterial infections.
67 Antibiotics that inhibit bacterial cell wall biosynthesis are therefore clinically important in the
68 treatment of infectious diseases. Understanding bacterial cell wall biosynthesis has been the subject of
69 intensive study from the time of the discovery of penicillin, the first clinically available antibiotic
70 targeting peptidoglycan biosynthesis, up to the present day in analyses of the distinct mode of action of
71 glycopeptide antibiotics such as vancomycin. Vancomycin inhibits the completion of bacterial cell wall
72 peptidoglycan biosynthesis by non-covalently binding to the terminus of growing peptidoglycan, D-

73 alanyl-D-alanine (D-Ala-D-Ala) (3). For more than 50 years, vancomycin has been reserved as an
74 antibiotic of last resort for the treatment of infectious diseases caused by Gram-positive bacteria,
75 particularly methicillin-resistant *Staphylococcus aureus* (MRSA). However, in common with the other
76 antibiotics in mainstream use, resistance to glycopeptides has spread through bacterial populations,
77 with the first clinical isolates of vancomycin-resistant Enterococci (VRE) being identified in the
78 1980's, and vancomycin-resistant MRSA (VRSA) emerging at the beginning of the new millennium
79 (4). It was soon revealed that these resistant strains have responded to the challenge of vancomycin by
80 replacement of the D-Ala-D-Ala terminus of peptidoglycan precursors with D-alanyl-D-lactate (D-Ala-
81 D-Lac) resulting in an approximately 1000-fold lower binding affinity for vancomycin and
82 consequently rendering the modified bacteria resistant to the antibiotic (3). This peptidoglycan
83 remodelling requires expression of at least three genes, *vanHAX*. Transcription of *vanHAX* is usually
84 regulated by VanS and VanR two-component system regulatory proteins and genes encoding these
85 proteins are often found adjacent to *vanHAX*.

86 Research into the mechanism of glycopeptide antibiotic resistance initially focused on the
87 pathogenic bacterial strains (5-7), but the complexity of the resistance system uncovered soon led to the
88 speculation that the resistance genes may have originated from an antibiotic producing organism where
89 they had co-evolved for self-protection. *Streptomyces coelicolor* is a model organism for the
90 actinomycetes, the genus responsible for the production of the two-thirds of clinically important
91 antibiotics (8). It does not synthesize any glycopeptide antibiotics but does possess a vancomycin
92 resistance cluster (*vanRSJKHAX*) (9). *S. coelicolor* has consequently emerged as a safe and convenient
93 model system for the in vivo study of glycopeptide resistance, and has provided a detailed
94 understanding both of the specific mechanisms of resistance and how these are integrated with the
95 more generalized mechanisms for bacterial cell wall homeostasis (9-17). This knowledge has allowed
96 us to develop some simple but effective bioassay tools for identifying antimicrobial agents that are

97 active against cell wall biosynthesis, and here we report their use to screen a large natural product
98 extract library for novel glycopeptide antibiotics.

99

100

101 **MATERIALS AND METHODS**

102

103 **Bacterial strains, media, oligonucleotides, and growth conditions.**

104 Bacterial strains, plasmids, oligonucleotides and media for this study are described in Tables S1-S3
105 respectively. Except where described here, media and culture conditions were as given previously (18).

106

107 **Construction of the natural product extract library.**

108 To establish the extract library, soil samples were first collected from diverse sites around south-eastern
109 Asia, focusing on environments with unusual weather conditions and ecologies e.g. alpine, tropical,
110 polar and desert regions. One gram of each soil sample was suspended in 10 ml of 0.85% NaCl solution
111 and serially diluted. The serial dilutions were spread on Humic acid-Vitamin (HV) agar medium (19) to
112 isolate actinomycete strains (see Table S2 in the supplemental material). After incubation at 30 °C for 7
113 days any single colony displaying a representative actinomycete morphology was isolated by streaking
114 on modified Bennett's (m-BN) agar medium or Gauze's No. 1 (GN1) agar medium (20) (see Table
115 S3). This also provided the opportunity to further confirm the actinomycete colony morphology. After
116 incubation at 30°C for an additional 7 days, the surface of each plate was scraped with sterile cotton
117 wool soaked in 20% glycerol solution. The cotton wool was then squeezed into an empty sterile tube to
118 collect the filtered spores or mycelium suspension of the selected actinomycete strain and stored at -80
119 °C.

120 For the preparation of the crude metabolite extracts, 0.5 ml of spore (or aerial mycelium) glycerol
121 stock solution of each isolate was inoculated in 30 ml each of three different liquid media; Bennett's
122 (BN) medium, Glucose Soybean Starch (GSS) medium, and Dextrin Yeast Corn steep liquor (DYC)
123 medium (Table S3). After incubation at 30 °C and 280 rpm for 6 days in a 250 ml sterile flask
124 containing a 30 cm coiled stainless steel spring baffle, each culture broth was centrifuged for 5 min at
125 1,500 g. The supernatant was poured into 30 ml of ethyl acetate and extracted for 5 min by vortexing
126 vigorously. Following phase separation, the ethyl acetate layer was evaporated to dryness and re-
127 dissolved in 3 ml methanol. The aqueous phase was mildly heated (60 °C) for 30 min to remove ethyl
128 acetate remained in aqueous phase and freeze-dried, then re-dissolved in 3 ml water. The cell pellet was
129 extracted with 3 ml of methanol by vigorous vortexing for 20 min then centrifuged for 5 min at 1,500 g
130 to remove cell debris. 30 µl aliquots of each extract were added to 96 well plates, freeze dried and
131 stored at 4 °C. Each actinomycete isolate consequently generates nine different extracts. The full
132 extract library currently consists of approximately 150,000 natural product extracts from over 15,000
133 different actinomycete strains. The library has been give the acronym ECUM (Extract Collection of
134 Useful Microorganisms) and is further described at www.ecum.or.kr.

135

136 **Screening the extract library and isolation of MJM2582.**

137 Each freeze-dried actinomycete extract aliquot from the 96 well plates was dissolved in 30 µl dimethyl
138 sulfoxide (DMSO) and 10 µl was used per screening assay. For the first-round screening using the
139 *sigEp-neo* fusion reporter system, approximately 10^7 spores of *S. coelicolor* M600 carrying pIJ6880 (a
140 multi-copy, promoter probe plasmid, pIJ486, carrying *sigEp-neo* fusion DNA; see Table S1 in the
141 supplemental material) were spread on 12 cm × 12 cm MMCGT agar plates containing 100 µg/ml of
142 kanamycin. 6 mm sterile paper discs impregnated with the 10 µl DMSO extract sample were applied to
143 the surface of the freshly spread plates, and activity scored after incubation at 30 °C for 2-4 days.

144 Positive inducers of the *sigE* promoter raise the level of expression of the *neo* gene and hence
145 produce a halo of kanamycin-resistant growth around the paper disc. The number of isolates tested for
146 the first-round screening was over 5,300, with ~260 strains (about 5%) giving a positive response.
147 These positive extracts were subjected to a second-round of screening using the $\Delta femX$ mutant strain to
148 identify those containing glycopeptide antibiotics capable of inducing *van* gene expression (explained
149 in detail in the Results section). Approximately 10^7 spores of *S. coelicolor* $\Delta femX$ mutant strain J3130
150 (see Table S1) were spread on MMCGT agar medium containing no antibiotic, and 10 μ l DMSO
151 solutions of the selected inducer extracts were applied on paper discs to the plate. Plates were incubated
152 at 30 °C for 2-4 days. Positive inducers produced a halo of glycopeptide-dependent growth of *S.*
153 *coelicolor* $\Delta femX$ around the disc.

154 A single strain, designated as *Amycolatopsis* species MJM2582, was isolated from the 260 tested
155 from the first round screen. Among the 9 different extracts from MJM2582 tested, very strong and clear
156 induction halo were all observed from extracts prepared from aqueous and methanol extracts. In
157 contrast, negligible halos were observed from extracts prepared from the ethyl acetate layer. This is
158 consistent with the water solubility and organic solvent insolubility of glycopeptide antibiotics.

159

160 **Genomic DNA extraction, sequencing and annotation.**

161 The genomic DNAs of MJM2582 and *Amycolatopsis lurida* were isolated by modification of the
162 ‘Kirby mix procedure’ according to the method described previously (18). Each strain was cultured in
163 10 ml Tryptic Soy Broth (TSB, Oxoid) liquid medium at 30 °C 280 rpm for 2 days. The harvested
164 mycelia were washed twice with an equal volume of 10.3% sucrose and then lysed in 1 ml of lysozyme
165 solution (2 mg/ml lysozyme in 10.3% sucrose, 25 mM Tris (pH8), 25 mM EDTA, pH8) by incubating
166 at 30 °C for 10 min. The lysate was extracted with 1 ml of 2 $\times$ Kirby mix (2 g sodium tri-
167 isopropylphenylmethane sulphonate, 12 g sodium 4-amino-salicylate, 5 ml 2 M tris-HCl (pH8), 6 ml

168 phenol mixture and made up to 100 ml with water) and 2 ml of phenol/chloroform solution
169 (phenol:chloroform (1:1 v/v), equilibrated with 0.1M Tris, pH8), and 1 ml of phenol/chloroform. The
170 nucleic acids in upper phase were transferred to a fresh tube and precipitated with 1/10 volume of 3 M
171 sodium acetate (pH6) and an equal volume of isopropanol at room temperature for 10 min. The pellet
172 of nucleic acids obtained by centrifugation was then resuspended in RNase solution (50 µg/ml of
173 RNaseI in 500 µl Tris-EDTA (TE) buffer) and incubated for 30 min at 37 °C to remove all RNAs. The
174 genomic DNA sample was cleaned by extraction with 200 µl of phenol/chloroform, and isopropanol
175 precipitation as described above. The DNA pellet obtained after centrifugation was washed with 70%
176 ethanol and dissolved in TE buffer solution (25 mM Tris (pH7.5), 2 ml EDTA).

177 Whole genome sequencing was performed by the DNA sequencing facility at the Department of
178 Biochemistry, University of Cambridge using a combined Illumina MiSeq and Roche 454 sequencing
179 approach. Assembly using the 454 GS De Novo Assembler (v.2.8) produced a draft sequence of 9.3
180 Mb in 149 contigs. Anti-SMASH 2.0 (<http://www.secondarymetabolites.org/>) (21, 22) was used to
181 identify a single glycopeptide gene cluster in each genome sequence. The DNA sequence of the cluster
182 from MJM2582 and *A. lurida* has been deposited in the GenBank database under accession number
183 KF882511 and KJ364518. Sequence comparison studies with previously reported glycopeptide
184 biosynthetic clusters i.e. teicoplanin, balhimycin, A47934, chloroeremomycin, dalbavancin and
185 vancomycin were performed using the ACT web comparison tool (23). Artemis (24) and Glimmer 3.02
186 (25) were used for prediction and annotation of open reading frames (Orfs) in the cluster sequence.

187

188 **Extraction and purification of glycopeptide antibiotics.**

189 Aerial mycelia (or spores) of each glycopeptide producer strain of interest (*Amycolatopsis* species
190 MJM2582, *Amycolatopsis lurida*, *Streptomyces toyocaensis*, *Amycolatopsis balhimycina*) (see Table S1
191 in the supplemental material) were prepared from 7 day cultures on Soya Flour Mannitol (SFM) agar

192 medium or BN agar medium at 30 °C (see Table S2). MJM2582 was tested for preparative
193 glycopeptide production in media previously reported for the production of A47934 (26), teicoplanin
194 (27), vancomycin (28) and ristocetin (29). Bioassays using *S. coelicolor* $\Delta femX$ and *S. coelicolor*
195 $\Delta vanRS$ strain showed that the only medium that reliably yielded glycopeptides was Streptomyces
196 Antibiotic Medium (SAM) used for A47934 biosynthesis (26). Seed cultures of MJM2582 were
197 prepared by transferring its mycelia (or spores) to 25 ml Glucose Yeast extract Malt extract (GYM)
198 liquid medium (20) in a 250 ml Erlenmeyer flask containing a 30 cm stainless steel spring wire and
199 incubating at 30 °C for 48 h with shaking at 250 rpm (see Table S3). 2.5 ml of dense seed culture was
200 then used to inoculate 50 ml SAM medium in 250 ml Erlenmeyer flasks containing spring wire baffles.
201 After incubation at 30 °C for 6 days with shaking at 250 rpm, the culture broth was centrifuged and the
202 cell pellet was extracted with 1% NH₄OH (1 ml per 1 g wet pellet). This mixture was centrifuged and
203 the alkaline supernatant harvested and neutralized with HCl. This pellet extract was used for initial
204 bioassay screening and a similar process was used to obtain glycopeptide extracts from *S. toyocaensis*
205 and *A. balhimycina*.

206 The MJM2582 glycopeptide was further purified by combining its pellet extract with the culture
207 supernatant, which was then applied to Diaion HP20 resin. The resin was washed with a step-wise
208 gradient of water and methanol to elute the bound glycopeptides (50-80% methanol). Fractions
209 containing glycopeptides were pooled and further purified using a D-Ala-D-Ala affinity resin. This was
210 prepared and used as previously described (30) and yielded a mixture of glycopeptides. Individual
211 glycopeptides were obtained by preparative HPLC (Agilent 1200) using a Phenomenex Luna C18(2)
212 column (250 mm × 21.2 mm, 10 µm), eluting with a linear gradient of 5 to 95% acetonitrile (+ 0.1%
213 TFA) in water (+ 0.1% TFA) over 35 min with a flow-rate of 20 ml/min. UV detection was performed
214 at 280 nm.

215

216 **Additional antibiotic bioassays.**

217 All other antibiotic susceptibility, resistance and induction tests using *S. coelicolor* strains were
218 performed on Minimal Medium plus Casaminoacids Glucose Tiger milk (MMCGT) agar medium (see
219 Table S2 in the supplemental material). Approximately 10^7 spores of *S. coelicolor* strains were spread
220 on 12 cm $\times$ 12 cm square plates, or for 9 cm diameter round plates 10^5 spores were used. 10-30 μ l of
221 antibiotic solution (containing 30 μ g antibiotic) was then soaked into sterile 6 mm paper discs and
222 applied to the freshly spread spore lawns and incubated at 30 °C for 2-4 days before scoring. For
223 antibiotic susceptibility tests using *Bacillus subtilis*, *Enterococcus faecalis* and *Staphylococcus aureus*,
224 plates were prepared by mixing a 200 μ l aliquot from an overnight liquid culture of each strain with 20
225 ml of just-molten LB soft agar (18) and set at room temperature. Plates were scored after incubation at
226 37 °C for 18 h. For bioassays using antibiotic solution made from commercially available antibiotic
227 powder, 30 μ g of antibiotic was applied. For bioassays performed using glycopeptide antibiotics
228 extracted from producer strains, 20 μ l of a neutralized NH_4OH extract solution was used. All tested
229 antibiotics were purchased either from Sigma-Aldrich or Oxoid.

230

231 **Mass spectrometry analysis of glycopeptide antibiotics.**

232 Glycopeptide antibiotics were analyzed by liquid chromatography - mass spectrometry (LC-MS;
233 Agilent 1100 HPLC coupled to a Thermo Scientific LCQ with an ESI source in positive-ion mode)
234 using a Phenomenex Luna C18(2) column (250 mm $\times$ 2.0 mm, 5 μ m), eluting with a linear gradient of
235 5 to 95% acetonitrile (+ 0.1% TFA) in water (+ 0.1% TFA) over 25 min with a flow-rate of 0.3 ml/min.
236 UV detection was performed at 280 nm. The major components after D-Ala-D-Ala resin purification
237 were m/z = 1773.3, 1759.3, 1034.3 and 1027.3. High-resolution mass spectrometry was recorded on a
238 Thermo Scientific LTQ Orbitrap and yielded the major component with an isotopic pattern of m/z =
239 1034.3386, 1034.8396, 1035.3406, 1035.8416, 1036.3429. This is identical to the pattern generated

240 from authentic ristocetin A ($[M+2H]^{2+}$; $C_{95}H_{112}N_8O_{44}^{2+}$) of $m/z = 1034.3385, 1034.8395, 1035.3404,$
241 $1035.8415, 1036.3427.$

242

243

244 RESULTS

245

246 **Extensive screening of microbial extracts library using a novel two-step bioassay system**
247 **identified an *Amycolatopsis* strain producing glycopeptide antibiotic.**

248 For this study, we have initially established a geographically diverse collection of actinomycete strains.
249 Each actinomycete strain was then cultured in three different liquid media and extracted with three
250 different solvents consequently generating a total nine different natural product extracts. A randomly
251 selected subset of this library covering ~5,300 actinomycete isolates was screened using a two-step
252 procedure involving an initial bioassay using a *sigEp-neo* fusion reporter strain to identify extracts
253 capable of triggering a generalized cell wall stress response (10), followed by a growth assay using a
254 $\Delta femX$ mutant strain to identify specific glycopeptide antibiotic activity (11, 12) (Fig. 1A). *sigE*
255 encodes an extracytoplasmic function (ECF) sigma factor, σ^E , which is part of a signal transduction
256 system that senses and responds to cell wall stress and is therefore required for normal cell wall
257 integrity in *S. coelicolor* (31). Expression of *sigE* is induced by a wide-variety of agents that stress the
258 cell wall, and wild-type *S. coelicolor* harbouring a multi-copy *sigEp-neo* fusion reporter plasmid
259 (pIJ6880; see Table S1 in the supplemental material) in which the aminoglycoside phosphotransferase
260 gene (*neo*) is expressed under the control of the *sigE* promoter only exhibits kanamycin-resistant
261 growth in the presence of such compounds (Fig. 1B). About 5% of the extracts tested strongly activated
262 expression of the *sigEp-neo* fusion, and these were subjected to a second round of screening using a
263 $\Delta femX$ mutant bioassay system. FemX adds a single branched glycine to the stem pentapeptide of

264 peptidoglycan precursors during cell wall biosynthesis, and is essential for growth under normal
265 conditions. During exposure to vancomycin however, induction of the *vanHAX* genes remodels
266 peptidoglycan biosynthesis to produce precursors with pentapeptide chains terminating with D-Ala-D-
267 Lac instead of D-Ala-D-Ala. This modification confers resistance to vancomycin but FemX cannot
268 efficiently use D-Ala-D-Lac-containing precursors as substrates, and under these growth conditions this
269 function is instead performed via induction of the homologous enzyme VanK. FemX therefore
270 becomes non-essential provided that the *van* genes are expressed (11). As a consequence, the $\Delta femX$
271 mutant strain is viable in the presence of vancomycin but non-viable in its absence, making growth of
272 the $\Delta femX$ mutant itself a simple drug-dependent bioassay system for specifically screening for
273 glycopeptide antibiotics (Fig. 1B). Of the 260 strains with extracts producing a positive response in the
274 first round screen, extracts from a single isolate were found to strongly induce $\Delta femX$ growth in the
275 glycopeptide bioassay. Susceptibility tests using vancomycin sensitive and resistant (inducible and
276 constitutive) bacterial strains provided further evidence for the presence of a glycopeptide antibiotic in
277 the positive extract (Fig. 1C; see also Fig. S1 in the supplemental material). The 16S rRNA gene
278 sequence of the producing strain was next determined as a filter to guard against the rediscovery of
279 known glycopeptide producer strains, and indicated a previously unidentified *Amycolatopsis* species
280 which we designated *Amycolatopsis* sp. MJM2582 (Fig. 2; see also Fig. S2).

281

282 ***Amycolatopsis* sp. MJM2582 produces ristocetin.**

283 To fully characterize the glycopeptide produced by MJM2582, a draft genome sequence was produced
284 to access the genes in the biosynthetic cluster, and culture extracts were analyzed using LC-MS.
285 Comparative analysis using sequences from a number of previously reported glycopeptide biosynthetic
286 clusters including teicoplanin (32), balhimycin (33), A47934 (34), dalbavancin (35) and vancomycin
287 (36), indicates that MJM2582 carries a novel ~79 kb gene cluster consisting of 39 Orfs (Fig. 3; see also

Fig. S3 and Table S4 in the supplemental material). LC-MS analysis identified a number of related glycopeptides produced by MJM2582. A single component eluting at 9.0 min and with $m/z = 1034$ is identical to an authentic standard of ristocetin A ($[M+2H]^{2+} = 1034$) indicating that the predicted structure of the glycopeptide from MJM2582 corresponds to ristocetin A (Fig. 4; see also Figs. S4 and S5 in the supplemental material). The other compounds are consistent with O-desmethyl ristocetin A ($[M+2H]^{2+} = 1027$), ristocetin B ($[M+H]^+ = 1773$) and O-desmethyl ristocetin B ($[M+H]^+ = 1759$) (Fig. 5; see also Fig. S6). This is the first report of the biosynthetic gene cluster for ristocetin, and identifies a second producer strain for this glycopeptide, which had previously been isolated from *Amycolatopsis lurida* (37). Genome sequencing of *A. lurida* showed that it carries a gene cluster with an identical organization and 91% nucleotide identity.

Analysis of the ristocetin gene cluster. In comparison to previously characterized glycopeptide clusters, the ristocetin cluster has a number of interesting and distinctive features (see Fig.S3 and Table S4 in the supplemental material). It possesses six genes encoding glycosyltransferase (GT) enzymes, which is more than any previously reported cluster and reflects the complex pattern of glycosylation in the antibiotic produced. Phylogenetic analysis of the GTs indicates the presence of four class B and two class C enzymes that handle the attachment of the D-arabinose, D-glucose, L-rhamnose, L-ristosamine and two D-mannose sugars to the ristocetin aglycone (see Fig. S7 in the supplemental material). Bacterial class C GTs catalyze mannosylation using undecaprenyl-phospho-mannose as a donor, whereas class B GTs utilize a wide variety of NDP-activated sugars (38). The sugars required for ristocetin production can all be accessed from generalized bacterial metabolism with the notable exception of L-ristosamine, a rare dideoxy sugar that requires dedicated genes in the cluster for its biosynthesis. We propose a route to TDP-activated L-ristosamine via activity of the enzymes encoded by Orfs 30-33 in the cluster (Fig. 6). These are homologous to genes in the chloroeremomycin cluster

312 which produce the related sugar epivancosamine (39), a methylated derivative of L-ristosamine
313 additionally requiring a 3-C-methyltransferase (MT) that is absent from the ristocetin cluster. Another
314 unusual feature of ristocetin is its methylation pattern: O-methylation of the carboxyl terminus of the
315 core peptide and C-methylation of (S)-3,5-dihydroxyphenylglycine (Dpg) at amino acid position 3.
316 Accordingly, two MTs are encoded in the gene cluster (see Fig. 3). Orf19 shares significant homology
317 with VEG18 which catalyses the C-terminal O-methylation of a glycopeptide aglycone (40) while
318 Orf23 does not share homology with any previously characterized glycopeptide MTs and is therefore
319 the candidate for the C-methylation of the ristocetin aglycone (see Table S4 in the supplemental
320 material). This modification is unique amongst characterized glycopeptide pathways.

321 The four non-ribosomal peptide synthetase (NRPS) proteins in the ristocetin gene cluster have a
322 similar domain organization and predicted adenylation domain specificity to the teicoplanin NRPS and
323 assemble a peptide from β -hydroxytyrosine (β HTy), (S)-4-hydroxyphenylglycine (Hpg) and Dpg (Fig.
324 7; see also Table S5 in the supplemental material) (41). The rigid teicoplanin-like ristocetin aglycone is
325 then predicted to be generated by four cytochrome P450 enzymes encoded by adjacent genes (Orfs12-
326 15), which in previously characterized pathways are known to form oxidative cross-links between the
327 aromatic amino acid side chains (32). Interestingly, while the organization of the NRPS into four
328 proteins with a module distribution of 2-1-3-1 is a feature common to teicoplanin-like (Type IV)
329 glycopeptides, the organization of the tailoring enzymes is much more closely related to vancomycin-
330 like (Type I) glycopeptides. Furthermore, while Dpg and Hpg biosynthesis is conserved between the
331 production of teicoplanin-like and vancomycin-like glycopeptides, distinct routes have evolved for
332 β HTy biosynthesis, where a single non-heme dioxygenase is used for the former (42), and three
333 separate enzymes for the latter (43). Ristocetin employs the same route as vancomycin (Orfs 25-27),
334 despite a teicoplanin-like aglycone. Ristocetin is the only non-chlorinated glycopeptide antibiotic
335 reported to date, and the gene cluster unsurprisingly does not encode a halogenase.

The 5'-end of the ristocetin gene cluster is marked by the presence of the *vanHAX* glycopeptide resistance system required for reprogramming cell wall peptidoglycan biosynthesis (see Fig. 3). However no genes encoding the VanRS two-component regulatory system were identified anywhere in both the MJM2582 and *S. lurida* genome, implying that *vanHAX* expression may be constitutive in this strain or otherwise controlled in a VanRS-independent manner. Interestingly, alignment of the *vanHAX* promoter sequence in ristocetin gene cluster with similar sequences from other glycopeptide gene clusters identified conserved nucleotide changes in those with no obvious VanRS control system in comparison to those known to be regulated by VanRS (Fig. 8). This implies that the putatively VanRS-independent promoters may share the same method of regulation.

DISCUSSION

We have identified the previously unknown ristocetin gene cluster encoding interesting new enzyme activities using a two-step screening system developed from an understanding of the detailed molecular mechanism of glycopeptide resistance in *S. coelicolor*. Thaker et al. recently reported the discovery of the novel glycopeptide pekiskomycin using growth in the presence of vancomycin as an initial screen to enrich for glycopeptide producing strains derived from soil samples (44). A significant proportion (89/100) of the vancomycin-resistant strains isolated in this way did not however contain glycopeptide biosynthetic clusters and it was necessary to include an additional PCR based screen to identify those that do. The $\Delta femX$ mutant bioassay employed in this work proved highly specific for compounds which induce expression of the van resistance genes, and a further discriminatory screen was not required. Nevertheless, Thaker et al. elegantly exploited the results of their PCR screen to produce phylogenetic fingerprints for dereplication, discriminating against the rediscovery of known strains and

360 compounds, and we believe that the two different screens can be highly complementary. Although
361 more limited in scope, both also offer significant advantages over the screening of metagenomic
362 libraries of DNA from soil for natural products biosynthetic clusters where the disconnection between
363 the producing microbe and the bioactivity of the molecules that are ultimately being sought introduces
364 a number of formidable technical challenges. Our focused approach has the advantage that any positive
365 screen hit apriori comes from an actinomycete strain which is both culturable and competent for the
366 biosynthesis of the detected antibiotic activity under laboratory conditions.

367 We envisage that the direct relationship between producing organism, genome sequence and
368 antibiotic activity afforded by our screening procedure will facilitate both the isolation of new
369 glycopeptide antibiotics, and the provision of novel verified enzyme activities for use in synthetic
370 biology approaches to explore the production and design of modified antibiotic structures. In addition,
371 the extracts identified as active in the first round of *sigEp-neo* screening but inactive in the subsequent
372 glycopeptide screen, and which were not considered further in this work, provide an enriched library
373 from which to seek other classes of natural products active against the bacterial cell wall. The native *S.*
374 *coelicolor* VanS sensor is not induced by teicoplanin-like compounds, and we are currently developing
375 hybrid sensors to broaden the range of glycopeptide structures that can be detected. Only the extracts
376 that produced a positive response in the *sigEp-neo* screen would need to be reanalyzed in the improved
377 hybrid screens.

378

379

380 **ACKNOWLEDGEMENTS**

381

382 This work was supported by funding from the Royal Society, UK (516002.K5877/ROG), the Medical
383 Research council, UK (G0700141) and St. John's College, University of Cambridge. We thank Andy

384 Hesketh (University of Cambridge, Systems Biology Centre) for helpful discussion and comments on
385 the manuscript.

386

387

388 REFERENCES

389

390 1. **Levy S, Marshall B.** 2004. Antibacterial resistance worldwide: causes, challenges and
391 responses. *Nat. Med.* **10**:S122-129.

392 2. **Wohlleben W, Mast Y, Muth G, Röttgen M, Stegmann E, Weber T.** 2012. Synthetic
393 biology of secondary metabolite biosynthesis in actinomycetes: Engineering precursor supply as a way
394 to optimize antibiotic production. *FEBS Lett.* **586**:2171-2176.

395 3. **Leclercq R, Derlot E, Duval J, Courvalin P.** 1988. Plasmid-mediated resistance to
396 vancomycin and teicoplanin in *Enterococcus faecium*. *N. Engl. J. Med.* **319**:157-161.

397 4. **Pearson H.** 2002 ‘Superbug’ hurdles key drug barrier. *Nature* **418**:469-470.

398 5. **Billot-Klein D, Gutmann L, Bryant D, Bell D, Van Heijenoort J, Grewal J, Shlaes DM.**
399 1996. Peptidoglycan synthesis and structure in *Staphylococcus haemolyticus* expressing increasing
400 levels of resistance to glycopeptide antibiotics. *J. Bacteriol.* **178**:4696-4703.

401 6. **Arthur M, Reynolds P, Courvalin P.** 1996. Glycopeptide resistance in enterococci. *Trends*
402 *Microbiol.* **4**:401-407.

403 7. **Courvalin P.** 2005. Genetics of glycopeptide resistance in gram-positive pathogens. *Int. J.*
404 *Med. Microbiol.* **294**:479-486.

405 8. **Bentley SD, Chater KF, Cerdano-Tárraga AM, Challis GL, Thomson NR, James KD,**
406 **Harris DE, Quail MA, Kieser H, Harper D, Bateman A, Brown S, Chandra G, Chen CW, Collins**
407 **M, Cronin A, Fraser A, Goble A, Hidalgo J, Hornsby T, Howarth S, Huang CH, Kieser T, Larke**

408 **L, Murphy L, Oliver K, O'Neil S, Rabbinowitsch E, Rajandream MA, Rutherford K, Rutter S,**
 409 **Seeger K, Saunders D, Sharp S, Squares R, Squares S, Taylor K, Warren T, Wietzorrek A,**
 410 **Woodward J, Barrell BG, Parkhill J, Hopwood DA.** 2002 Complete genome sequence of the model
 411 actinomycete *Streptomyces coelicolor* A3(2). *Nature* **417**:141-147.

412 9. **Hong H-J, Hutchings MI, Neu JM, Wright GD, Paget MS, Buttner MJ.** 2004.
 413 Characterisation of an inducible vancomycin resistance system in *Streptomyces coelicolor* reveals a
 414 novel gene (*vanK*) required for drug resistance. *Mol. Microbiol.* **52**:1107-1121.

415 10. **Hong H-J, Paget MSB, Buttner MJ.** 2002. A signal transduction system in *Streptomyces*
 416 *coelicolor* that activates the expression of a putative cell wall glycan operon in response to vancomycin
 417 and other cell wall-specific antibiotics. *Mol. Microbiol.* **44**:1199-1211.

418 11. **Hong H-J, Hutchings MI, Hill L, Buttner MJ.** 2005. The role of the novel Fem protein VanK
 419 in vancomycin resistance in *Streptomyces coelicolor*. *J. Biol. Chem.* **280**:13055-13061.

420 12. **Hutchings MI, Hong H-J, Buttner MJ.** 2006. The vancomycin resistance VanRS signal
 421 transduction system of *Streptomyces coelicolor*. *Mol. Microbiol.* **59**:923-935.

422 13. **Hutchings MI, Hong H-J, Leibovitz E, Sutcliffe IC, Buttner MJ.** 2006. The σ^E cell envelope
 423 stress signal of *Streptomyces coelicolor* is influenced by a novel lipoprotein, CseA. *J. Bacteriol.*
 424 **188**:7222-7229.

425 14. **Koteva K, Hong H-J, Wang XD, Nazi I, Hughes D, Naldrett MJ, Buttner MJ, Wright GD.**
 426 2010. A vancomycin photoprobe identifies the histidine kinase VanSsc as a vancomycin receptor. *Nat.*
 427 *Chem. Biol.* **6**:327-329.

428 15. **Hesketh A, Hill C, Mokhtar J, Novotna G, Tran N, Bibb M, Hong H-J.** 2011. Genome-wide
 429 dynamics of a bacterial response to antibiotics that target the cell envelope. *BMC genomics* **12**:226.
 430 doi: 10.1186/1471-2164-12-226.

- 431 16. **Novotna G, Hill C, Vicent K, Liu C, Hong H-J.** 2012. A novel membrane protein, VanJ,
432 conferring resistance to teicoplanin. *Antimicrob. Agents Chemother.* **56**:1784-1796.
- 433 17. **Kwun MJ, Novotna G, Hesketh AR, Hill L, Hong H-J.** 2013. In vivo studies suggest that
434 induction of VanS-dependent vancomycin resistance requires binding of the drug to D-Ala-D-Ala
435 termini in the peptidoglycan cell wall. *Antimicrob. Agents Chemother.* **57**:4470-4480.
- 436 18. **Kieser T, Bibb MJ, Buttner MJ, Chater KF, Hopwood DA.** 2000. Practical *Streptomyces*
437 Genetics, The John Innes Foundation, Norwich, UK.
- 438 19. **Masayuki H, Hideo N.** 1987. Humic acid-vitamin agar, a new medium for the selective
439 isolation of soil actinomycetes. *J. Ferment. Technol.* **65**:501-509.
- 440 20. **Atlas RM.** 2004. Handbook of microbiological media, CRC press.
- 441 21. **Medema MH, Blin K, Cimermancic P, de Jager V, Zakrzewski P, Fischbach MA, Weber**
442 **T, Takano E, Breitling R.** 2011. antiSMASH: rapid identification, annotation and analysis of
443 secondary metabolite biosynthesis gene clusters in bacterial and fungal genome sequences. *Nucleic*
444 *Acids Res.* **39**:W339-W346. doi: 10.1093/nar/gkr466. Epub 2011 Jun 14.
- 445 22. **Blin K, Medema MH, Kazempour D, Fischbach MA, Breitling R, Takano E, Weber T.**
446 2013. antiSMASH 2.0--a versatile platform for genome mining of secondary metabolite producers.
447 *Nucleic Acids Res.* **41**:W204-W212. doi: 10.1093/nar/gkt449. Epub 2013 Jun 3.
- 448 23. **Carver T, Berriman M, Tivey A, Patel C, Böhme U, Barrell BG, Parkhill J, Rajandream**
449 **MA.** 2008. Artemis and ACT: viewing, annotating and comparing sequences stored in a relational
450 database. *Bioinformatics* **24**:2672-2676.
- 451 24. **Rutherford K, Parkhill J, Crook J, Horsnell T, Rice P, Rajandream MA, Barrell B.** 2000.
452 Artemis: sequence visualization and annotation. *Bioinformatics* **16**:944-945.
- 453 25. **Delcher AL, Bratke KA, Powers EC, Salzberg SL.** 2007. Identifying bacterial genes and
454 endosymbiont DNA with Glimmer. *Bioinformatics* **23**:673-679.

- 455 26. **Neu JM, Wright GD.** 2001. Inhibition of sporulation, glycopeptide antibiotic production and
456 resistance in *Streptomyces toyocaensis* NRRL 15009 by protein kinase inhibitors. FEMS Microbiol.
457 Lett. **199**:15-20.
- 458 27. **Lee JC, Park HR, Park DJ, Son KH, Yoon KH, Kim YB, Kim CJ.** 2003. Production of
459 teicoplanin by a mutant of *Actinoplanes teicomyceticus*. Biotechnol. Lett. **25**:537-540.
- 460 28. **McIntyre JJ, Bull AT, Bunch AW.** 1996. Vancomycin production in batch and continuous
461 culture. Biotechnol. Bioeng. **49**:412-420.
- 462 29. **Philip JE, Forest L, Schenck JR.** 1961. Preparation of ristocetin A salts, US patent 2990329
463 A.
- 464 30. **Holding AN, Spencer JB.** 2008. Investigation into the mechanism of phenolic Ccouplings
465 during the biosynthesis of glycopeptide antibiotics. ChemBioChem **9**:2209-2214.
- 466 31. **Paget MSB, Emmanuelle L, Buttner MJ.** 1999. A putative two-component signal
467 transduction system regulates σ^E , a sigma factor required for normal cell wall integrity in *Streptomyces*
468 *coelicolor* A3(2). Mol. Microbiol. **33**:97-107.
- 469 32. **Li TL, Huang F, Haydock SF, Mironenko T, Leadlay PF, Spencer JB.** 2004. Biosynthetic
470 gene cluster of the glycopeptide antibiotic teicoplanin: characterization of two glycosyltransferases and
471 the key acyltransferase. Chem. Biol. **11**:107-119.
- 472 33. **Shawky RM, Puk O, Wietzorrek A, Pelzer S, Takano E, Wohlleben W, Stegmann E.** 2007.
473 The border sequence of the balhimycin biosynthesis gene cluster from *Amycolatopsis balhimycina*
474 contains *bbr*, encoding a StrR-like pathway-specific regulator. J. Mol. Microbiol. Biotechnol. **13**:76-88.
- 475 34. **Pootoolal J, Thomas MG, Marshall CG, Neu JM, Hubbard BK, Walsh CT, Wright GD.**
476 2002. Assembling the glycopeptide antibiotic scaffold: The biosynthesis of A47934 from *Streptomyces*
477 *toyocaensis* NRRL15009. Proc. Natl. Acad. Sci. U.S.A. **99**:8962-8967.

- 478 35. **Sosio M, Stinchi S, Beltrametti F, Lazzarini A, Donadio S.** 2003. The gene cluster for the
479 biosynthesis of the glycopeptide antibiotic A40926 by *nonomuraea* species. Chem. Biol. **10**:541-549.
- 480 36. **Jeong H, Sim YM, Kim HJ, Lee DW, Lim SK, Lee SJ.** 2013. Genome sequence of the
481 vancomycin-producing *Amycolatopsis orientalis* subsp. *orientalis* strain KCTC 9412T. Genome
482 Announc. **1**:e00408-00413. doi: 10.1128/genomeA.00408-13.
- 483 37. **Grundy WE, Sinclair AC, Theriault RJ, Goldstein AW, Rickher CJ, Warren Jr HB,
484 Oliver TJ, Sylvester JC.** 1956-1957. Ristocetin, microbiologic properties. Antibiot. Annu. 687-692.
- 485 38. **Coutinho PM, Deleury E, Davies GJ, Henrissat B.** 2003. An evolving hierarchical family
486 classification for glycosyltransferases. J. Mol. Biol. **328**:307-317.
- 487 39. **Chen H, Thomas MG, Hubbard BK, Losey HC, Walsh CT, Burkart MD.** 2000.
488 Deoxysugars in glycopeptide antibiotics: enzymatic synthesis of TDP-L-epivancosamine in
489 chloroeremomycin biosynthesis. Proc. Natl. Acad. Sci. U.S.A. **97**:11942-11947.
- 490 40. **Banik JJ, Brady SF.** 2008. Cloning and characterization of new glycopeptide gene clusters
491 found in an environmental DNA megalibrary. Proc. Natl. Acad. Sci. U.S.A. **105**:17273-17277.
- 492 41. **Donadio S, Sosio M, Stegmann E, Weber T, Wohlleben W.** 2005. Comparative analysis and
493 insights into the evolution of gene clusters for glycopeptide antibiotic biosynthesis. Mol. Genet.
494 Genomics **274**:40-50.
- 495 42. **Stinchi S, Carrano L, Lazzarini A, Feroggio M, Grigoletto A, Sosio M, Donadio S.** 2006. A
496 derivative of the glycopeptide A40926 produced by inactivation of the β -hydroxylase gene in
497 *Nonomuraea* sp. ATCC39727. FEMS Microbiol. Lett. **256**:229-235..
- 498 43. **Mulyani S, Egel E, Kittel C, Turkanovic S, Wohlleben W, Süssmuth RD, van Pée KH.**
499 2010. The thioesterase Bhp is involved in the formation of beta-hydroxytyrosine during balhimycin
500 biosynthesis in *Amycolatopsis balhimycina*. ChemBioChem **11**:266-271.

501 44. Thaker MN, Wang W, Spanogiannopoulos P, Waglechner N, King AM, Medina R,
502 Wright GD. 2013. Identifying producers of antibacterial compounds by screening for antibiotic
503 resistance. Nat. Biotechnol. **31**:922-927.

504

505

506 FIGURE LEGENDS

507

508 **FIG 1** Screening for novel glycopeptide antibiotics. (A) Schematic diagram illustrating the application
509 of a two-step cell wall bioactivity screen to a natural product extract library. Each isolated
510 actinomycete strain was cultured in three different liquid media and extracted with three different
511 solvents creating a total nine extracts per strain. Extracts from approximately 5,300 different isolates
512 were tested in the first round *sigEp-neo* fusion reporter system, and 260 different isolates gave extracts
513 which acted as strong inducers. Extracts from these 260 isolates were then subjected to a second round
514 of screening using $\Delta femX$ to identify glycopeptide antibiotics, yielding a single positive isolate
515 designated MJM2582. (B) Plates demonstrating the response of the *sigEp-neo*, $\Delta femX$ reporter systems
516 to antibiotics (numbered list shown). Antibiotics that target DNA gyrase (novobiocin), the ribosome
517 (thiostrepton) or early peptidoglycan biosynthesis (tunicamycin) do not induce the *sigEp-neo* system,
518 while those targeting late peptidoglycan biosynthesis (bacitracin, moenomycin A, ramoplanin,
519 vancomycin, teicoplanin, ristocetin) do. The amount of novobiocin, thiostrepton and tunicamycin used
520 in the bioassays (30 μ g each) is sufficient to produce a halo of growth inhibition when assayed against
521 *S. coelicolor*. Extracts obtained from known glycopeptide producer strains (*A. balhimycina*, *S.*
522 *toyocaensis*) and from MJM2582 also induced the *sigEp-neo* system. Only glycopeptide antibiotics
523 (but not teicoplanin) or extracts containing glycopeptides, including MJM2582, acted as inducers in the
524 $\Delta femX$ bioassay. (C) Bioassay showing the spectrum of activity of the MJM2582 extract against

glycopeptide sensitive ($\Delta vanRS$), constitutively resistant ($\Delta vanS$) and inducibly resistant (M600) strains of *S. ceolicolor*.

FIG 2 Phylogenetic analysis of MJM2582 16S RNA sequences. The result indicates that MJM2582 is a previously unidentified *Amycolatopsis* species. Scale bar indicates the distance in substitutions per nucleotide. See also Fig.S2 in the supplemental material.

FIG 3 Genetic organization of the glycopeptide gene cluster identified in *Amycolatopsis* sp. MJM2582. Predicted Orfs are represented by arrows, and numbered consecutively. The predicted enzymatic function encoded by each Orf is listed. A detailed comparison to the previously reported glycopeptide clusters can be found in Fig. S3 and Table S4 in the supplemental material.

FIG 4 LC-MS analysis of the purified glycopeptide extracted from (A) MJM2582 in comparison with (B) authentic ristocetin A. (C) The predicted structure of the glycopeptide from MJM2582 corresponds to ristocetin A.

FIG 5 LC-MS analysis of the array of glycopeptides produced by MJM2582 following partial purification using HP20 resin. (A) UV chromatogram for the extract and selective ion monitoring spectra for glycopeptides. (B) Mass spectra for each ristocetin derivative. The spectrometer was tuned to the $[M+2H]^{2+}$ ion of teicoplanin to facilitate the identification of compounds above 2000 Da. (C) Structures and exact masses of ristocetin A and B, and their corresponding desmethyl derivatives.

547 **FIG 6** The predicted formation of TDP-ristosamine. The route to TDP-ristosamine was proposed based
548 on homology of proteins encoded by Orfs 30-33 in the ristocetin gene cluster to the proteins previously
549 characterized in the TDP-epivancosamine pathway (39).

550

551 **FIG 7** Schematic showing the organization of the four NRPSs from the ristocetin gene cluster. The "X"
552 domain is a non-functional condensation-like domain that is present in all glycopeptide NRPSs (41).

553

554 **FIG 8** Alignment of *van* promoter sequences present in the glycopeptide antibiotic clusters from
555 *Streptomyces coelicolor* (Sc), *Streptomyces toyocaensis* (St), *Actinoplanes teichomyceticus* (At),
556 *Amycolatopsis balhimycina* (Ab), *Amycolatopsis orientalis* (Ao), *Amycolatopsis lurida* (Al) and
557 *Amycolatopsis* sp. MJM2582 (MJM). The highly conserved sequences represent a putative VanR
558 response regulator binding site in the -35 and -10 promoter region (boxed). The top four strains (Sc, St,
559 At, Ab) carry glycopeptide resistance clusters which include genes encoding a VanRS two-component
560 system, while the bottom three strains (Ao, Al and MJM) lack an obvious VanRS system. Nucleotide
561 sequence differences identified between these two groups are highlighted.




FIG 1 Screening for novel glycopeptide antibiotics. (A) Schematic diagram illustrating the application of a two-step cell wall bioactivity screen to a natural product extract library. Each isolated actinomycete strain was cultured in three different liquid media and extracted with three different solvents creating a total nine extracts per strain. Extracts from approximately 5,300 different isolates were tested in the first round *sigEp-neo* fusion reporter system, and 260 different isolates gave extracts which acted as strong inducers. Extracts from these 260 isolates were then subjected to a second round of screening using Δf_{emX} to identify glycopeptide antibiotics, yielding a single positive isolate designated MJM2582. (B) Plates demonstrating the response of the *sigEp-neo*, Δf_{emX} reporter systems to antibiotics (numbered list shown). Antibiotics that target DNA gyrase (novobiocin), the ribosome (thiostrepton) or early peptidoglycan biosynthesis (tunicamycin) do not induce the *sigEp-neo* system, while those targeting late peptidoglycan biosynthesis (bacitracin, moenomycin A, ramoplanin, vancomycin, teicoplanin, ristocetin) do. The amount of novobiocin, thiostrepton and tunicamycin used in the bioassays (30 μ g each) is sufficient to produce a halo of growth inhibition when assayed against *S. coelicolor*. Extracts obtained from known glycopeptide producer strains (*A. balhimycina*, *S. toyocaensis*) and from MJM2582 also induced the *sigEp-neo* system. Only glycopeptide antibiotics (but not teicoplanin) or extracts containing glycopeptides, including MJM2582, acted as inducers in the Δf_{emX} bioassay. (C) Bioassay showing the spectrum of activity of the MJM2582 extract against glycopeptide sensitive ($\Delta vanRS$), constitutively resistant ($\Delta vanS$) and inducibly resistant (M600) strains of *S. coelicolor*.




FIG 2 Phylogenetic analysis of MJM2582 16S RNA sequences. The result indicates that MJM2582 is a previously unidentified *Amycolatopsis* species. Scale bar indicates the distance in substitutions per nucleotide.




FIG 3 Genetic organization of the glycopeptide gene cluster identified in *Amycolatopsis* sp. MJM2582. Predicted Orfs are represented by arrows, and numbered consecutively. The predicted enzymatic function encoded by each Orf is listed. A detailed comparison to the previously reported glycopeptide clusters can be found in Fig. S3 and Table S4 in the supplemental material.




FIG 4 LC-MS analysis of the purified glycopeptide extracted from (A) MJM2582 in comparison with (B) authentic ristocetin A. (C) The predicted structure of the glycopeptide from MJM2582 corresponds to ristocetin A.




FIG 5 LC-MS analysis of the array of glycopeptides produced by MJM2582 following partial purification using HP20 resin. (A) UV chromatogram for the extract and selective ion monitoring spectra for glycopeptides. (B) Mass spectra for each ristocetin derivative. The spectrometer was tuned to the $[M+2H]^{2+}$ ion of teicoplanin to facilitate the identification of compounds above 2000 Da. (C) Structures and exact masses of ristocetin A and B, and their corresponding desmethyl derivatives.




FIG 6 The predicted formation of TDP-ristosamine. The route to TDP-ristosamine was proposed based on homology of proteins encoded by Orfs 30-33 in the ristocetin gene cluster to the proteins previously characterized in the TDP-epivancosamine pathway (39).




FIG 7 Schematic showing the organization of the four NRPSs from the ristocetin gene cluster. The "X" domain is a non-functional condensation-like domain that is present in all glycopeptide NRPSs (41).

				-35		-10	
Sc	vanJp	-----TCGCCACATATCGTCGGCATATCGAAAAAC	CGCATA	CGTGC	CGGCAACACGCTGCC	GCCTTCACTGGGCGT	-ATGCGT
	vanKp	-----CCGGAACATATCGTCGGCGTATCGAAAAAC	CGCATA	CGCGT	CGGCAACGTCCCGCG	GCCTTGACTGGGCGC	-ATGGCC
	vanHp	-----AGGTAATATATCGTCAGGATATCGAAAAG	CGCATA	CGGGA	CGGCAACACCGAGGC	GCCTTGAATAGAGG	-ATGACC
St	vanHp	-----GCGGGGCGTATCGCGGCATATCGAAAAG	CACATA	CGTTG	CGGCAACAGCACTT	CCCTTGACTGGAGG	-ATGACC
At	vanHp	GGGCCCCCTCCGACGTATCGTCGGCATATCCAAAAC	CGCATA	CGTGC	TCGCAACACCACCTT	CCCTTGACTGGGCGC	-ATGGGT
Ab	vanYp	-----ACATATCGTCGGCATATGGAAAAT	CGCATA	CGTGC	CGGCAACACATCGCG	GAATTGAATGGACAC	-ATGACC
Ao	vanHp	-----TGGTAACTTATGTCGGGGCATCGAAAAC	CCCATA	AAGAAG	CGGCAACAACGCGCT	GCCTTCAATGTCGGGC	ATGACC
Al	vanHp	-----TGGTAACTTATGTCGAGGCCTCGAAAAC	CCCATA	AAGAAG	CGGCAACATCGCGCT	GCCTTCAATGTCGGGC	ATGACC
MJM	vanHp	-----TGGTAACTTATGTCGGGGCATCGAAAAC	CCCATA	AAGAAG	CGGCAACAACGCGCT	GCCTTCAATGTCGGGC	ATGACC

FIG 8 Alignment of *van* promoter sequences present in the glycopeptide antibiotic clusters from *Streptomyces coelicolor* (Sc), *Streptomyces toyocaensis* (St), *Actinoplanes teichomyceticus* (At), *Amycolatopsis balhimycina* (Ab), *Amycolatopsis orientalis* (Ao), *Amycolatopsis lurida* (Al) and *Amycolatopsis* sp. MJM2582 (MJM). The highly conserved sequences represent a putative VanR response regulator binding site in the -35 and -10 promoter region (boxed). The top four strains (Sc, St, At, Ab) carry glycopeptide resistance clusters which include genes encoding a VanRS two-component system, while the bottom three strains (Ao, Al and MJM) lack an obvious VanRS system. Nucleotide sequence differences identified between these two groups are highlighted.